<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01267864</url>
  </required_header>
  <id_info>
    <org_study_id>10-01-009</org_study_id>
    <nct_id>NCT01267864</nct_id>
  </id_info>
  <brief_title>Valproate Versus Ketorolac Versus Metoclopramide</brief_title>
  <official_title>IV Valproate for Acute Migraine. A Randomized Comparison Versus IV Metoclopramide and IV Ketorolac</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized study is testing 3 different intravenous medications to see which one is best
      for acute migraine. The three medications are metoclopramide, valproate, and ketorolac.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One million patients present to US emergency departments (ED) annually for treatment of acute
      migraine headache. A variety of parenteral medications are used to treat acute migraine, but
      none offer rapid and complete headache relief without side effects. Preliminary studies have
      suggested that intravenous valproate, an anti-epileptic medication with established efficacy
      as a migraine preventive, may be useful for the treatment of acute migraine. We propose a
      randomized, comparative efficacy trial in which intravenous valproate is compared to two
      standard parenteral therapies for acute migraine. There will not be a placebo control.
      Included subjects will be adults 64 years and younger who meet International Headache Society
      criteria for acute migraine, who do not have clinical evidence of secondary (organic)
      headache, and who do not have allergy or contra-indication to the investigational
      medications. The investigational medications are 1gm of valproate, 10mg of metoclopramide,
      and 30mg of ketorolac. Patients will be approached for participation and randomized at the
      time of presentation to the ED. Pain will be assessed on an 11 point (0 to 10) verbal pain
      scale, validated for use in acute pain trials. Medication will be infused as a slow
      intravenous drip. The primary outcome will be an improvement in headache intensity one hour
      after initiation of the intravenous drip. Secondary outcomes include assessments of pain,
      functional disability, adverse events, and satisfaction with the investigational medication
      one, two and 24 hours after initiation of the intravenous drip. The primary analysis will use
      a Student's t-test for independent samples and involve three pair-wise comparisons. Using an
      alpha of .017 (to account for the three pairwise comparisons), a standard beta, and a
      validated minimum clinically significant difference on the verbal pain scale, we calculated
      the need for 330 subjects. An interim analysis will be conducted to determine lack of
      efficacy of valproate.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Headache Pain Level on a 0-10 Verbal Scale</measure>
    <time_frame>60 minutes after receipt of medication</time_frame>
    <description>Verbal Numerical Rating scale for pain. Absolute change from baseline. This is a 0-10 scale on which 0= no pain and 10= the worst pain imaginable.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants Who Achieve Sustained Headache Freedom for 24 Hours</measure>
    <time_frame>2- 24 hours after receipt of medication</time_frame>
    <description>Number of participants achieving a pain free state within two hours and maintaining the pain free state for 24 hours after receipt of medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction With Medication</measure>
    <time_frame>24 hours</time_frame>
    <description>% who answer the following question affirmatively at 24 hours: Do you want to receive the same medication the next time you present to an ER with an acute migraine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>24 hours</time_frame>
    <description>% who report any adverse event after administration of investigational medication</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">330</enrollment>
  <condition>Acute Migraine</condition>
  <arm_group>
    <arm_group_label>Metoclopramide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Metoclopramide 10mg IVSS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketorolac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ketorolac 30mg IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valproate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1gm IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metoclopramide</intervention_name>
    <description>10mg IVSS</description>
    <arm_group_label>Metoclopramide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac</intervention_name>
    <description>30g IVSS</description>
    <arm_group_label>Ketorolac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproate</intervention_name>
    <description>1gm IVSS</description>
    <arm_group_label>Valproate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  IHS migraine without aura

          -  IHS probable migraine (all migraine without arua criteria must be met except duration
             may be &gt;72 hours or &lt;4 hours)

        Exclusion Criteria:

          -  Allergy or contra-indication to investigational medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>December 15, 2010</study_first_submitted>
  <study_first_submitted_qc>December 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2010</study_first_posted>
  <results_first_submitted>March 25, 2014</results_first_submitted>
  <results_first_submitted_qc>May 31, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 4, 2018</results_first_posted>
  <last_update_submitted>May 31, 2018</last_update_submitted>
  <last_update_submitted_qc>May 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Benjamin W. Friedman, MD</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>migraine</keyword>
  <keyword>emergency</keyword>
  <keyword>metoclopramide</keyword>
  <keyword>ketorolac</keyword>
  <keyword>valproate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
    <mesh_term>Metoclopramide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Metoclopramide</title>
          <description>Metoclopramide 10mg IVSS
Metoclorpamide: 10mg IVSS</description>
        </group>
        <group group_id="P2">
          <title>Ketorolac</title>
          <description>Ketorolac 30mg IV
Ketorolac: 30g IVSS</description>
        </group>
        <group group_id="P3">
          <title>Valproate</title>
          <description>1gm IV
Valproate: 1gm IVSS</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="110"/>
                <participants group_id="P3" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="110"/>
                <participants group_id="P3" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metoclopramide</title>
          <description>Metoclopramide 10mg IVSS
Metoclorpamide: 10mg IVSS</description>
        </group>
        <group group_id="B2">
          <title>Ketorolac</title>
          <description>Ketorolac 30mg IV
Ketorolac: 30g IVSS</description>
        </group>
        <group group_id="B3">
          <title>Valproate</title>
          <description>1gm IV
Valproate: 1gm IVSS</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="110"/>
            <count group_id="B2" value="110"/>
            <count group_id="B3" value="110"/>
            <count group_id="B4" value="330"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34" lower_limit="26" upper_limit="44"/>
                    <measurement group_id="B2" value="34" lower_limit="25" upper_limit="44"/>
                    <measurement group_id="B3" value="33" lower_limit="25" upper_limit="41"/>
                    <measurement group_id="B4" value="33" lower_limit="25" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="91"/>
                    <measurement group_id="B4" value="276"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Headache Pain Level on a 0-10 Verbal Scale</title>
        <description>Verbal Numerical Rating scale for pain. Absolute change from baseline. This is a 0-10 scale on which 0= no pain and 10= the worst pain imaginable.</description>
        <time_frame>60 minutes after receipt of medication</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Metoclopramide</title>
            <description>Metoclopramide 10mg IVSS
Metoclorpamide: 10mg IVSS</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac</title>
            <description>Ketorolac 30mg IV
Ketorolac: 30g IVSS</description>
          </group>
          <group group_id="O3">
            <title>Valproate</title>
            <description>1gm IV
Valproate: 1gm IVSS</description>
          </group>
        </group_list>
        <measure>
          <title>Headache Pain Level on a 0-10 Verbal Scale</title>
          <description>Verbal Numerical Rating scale for pain. Absolute change from baseline. This is a 0-10 scale on which 0= no pain and 10= the worst pain imaginable.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="4.2" upper_limit="5.2"/>
                    <measurement group_id="O2" value="3.9" lower_limit="3.3" upper_limit="4.5"/>
                    <measurement group_id="O3" value="2.8" lower_limit="2.3" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Who Achieve Sustained Headache Freedom for 24 Hours</title>
        <description>Number of participants achieving a pain free state within two hours and maintaining the pain free state for 24 hours after receipt of medication</description>
        <time_frame>2- 24 hours after receipt of medication</time_frame>
        <population>Please note that 1 patient in the metoclopramide arm and 1 patient in the ketorolac arm were lost-to-follow-up and did not provide data for this outcome</population>
        <group_list>
          <group group_id="O1">
            <title>Metoclopramide</title>
            <description>Metoclopramide 10mg IVSS
Metoclorpamide: 10mg IVSS</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac</title>
            <description>Ketorolac 30mg IV
Ketorolac: 30g IVSS</description>
          </group>
          <group group_id="O3">
            <title>Valproate</title>
            <description>1gm IV
Valproate: 1gm IVSS</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Who Achieve Sustained Headache Freedom for 24 Hours</title>
          <description>Number of participants achieving a pain free state within two hours and maintaining the pain free state for 24 hours after receipt of medication</description>
          <population>Please note that 1 patient in the metoclopramide arm and 1 patient in the ketorolac arm were lost-to-follow-up and did not provide data for this outcome</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Satisfaction With Medication</title>
        <description>% who answer the following question affirmatively at 24 hours: Do you want to receive the same medication the next time you present to an ER with an acute migraine</description>
        <time_frame>24 hours</time_frame>
        <population>Study participants were telephoned 24 hours after medication administration. 3 patients in the metoclopramide arm, 4 in the ketorolac arm, and 3 in the valproate arm were lost to follow-up and did not provide these data. Additionally, 1 patient in the ketorolac arm did not provide an answer to this question</population>
        <group_list>
          <group group_id="O1">
            <title>Metoclopramide</title>
            <description>Metoclopramide 10mg IVSS
Metoclorpamide: 10mg IVSS</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac</title>
            <description>Ketorolac 30mg IV
Ketorolac: 30g IVSS</description>
          </group>
          <group group_id="O3">
            <title>Valproate</title>
            <description>1gm IV
Valproate: 1gm IVSS</description>
          </group>
        </group_list>
        <measure>
          <title>Satisfaction With Medication</title>
          <description>% who answer the following question affirmatively at 24 hours: Do you want to receive the same medication the next time you present to an ER with an acute migraine</description>
          <population>Study participants were telephoned 24 hours after medication administration. 3 patients in the metoclopramide arm, 4 in the ketorolac arm, and 3 in the valproate arm were lost to follow-up and did not provide these data. Additionally, 1 patient in the ketorolac arm did not provide an answer to this question</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Event</title>
        <description>% who report any adverse event after administration of investigational medication</description>
        <time_frame>24 hours</time_frame>
        <population>Any adverse event reported at any assessment throughout the study period.</population>
        <group_list>
          <group group_id="O1">
            <title>Metoclopramide</title>
            <description>Metoclopramide 10mg IVSS
Metoclorpamide: 10mg IVSS</description>
          </group>
          <group group_id="O2">
            <title>Ketorolac</title>
            <description>Ketorolac 30mg IV
Ketorolac: 30g IVSS</description>
          </group>
          <group group_id="O3">
            <title>Valproate</title>
            <description>1gm IV
Valproate: 1gm IVSS</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Event</title>
          <description>% who report any adverse event after administration of investigational medication</description>
          <population>Any adverse event reported at any assessment throughout the study period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were assessed for two hours in the emergency department after medication administration and then by telephone 24 hours later.</time_frame>
      <desc>Please note: 3 patients in the metoclopramide arm, 5 in the ketorolac arm, and 3 in the valproate arm did not provide data about restlessness.
Also, 1 patient in the metoclopramide arm did not provide any adverse event data.
Please note: Patients who reported an adverse event but did not detail what their symptom was are counted as &quot;other&quot;</desc>
      <group_list>
        <group group_id="E1">
          <title>Metoclopramide</title>
          <description>Metoclopramide 10mg IVSS
Metoclorpamide: 10mg IVSS</description>
        </group>
        <group group_id="E2">
          <title>Ketorolac</title>
          <description>Ketorolac 30mg IV
Ketorolac: 30g IVSS</description>
        </group>
        <group group_id="E3">
          <title>Valproate</title>
          <description>1gm IV
Valproate: 1gm IVSS</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="110"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <description>Any other adverse event</description>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="109"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="110"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Restless</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>24 hours after medication administration, we asked patients whether they had felt restless at any time after receiving the IV medication in the ED.</description>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="109"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="110"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Too drowsy to function after receiving investigational medication</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="110"/>
              </event>
              <event>
                <sub_title>Dizzy</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="109"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="110"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="110"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Benjamin Friedman, MD</name_or_title>
      <organization>Albert Einstein College of Medicine, Montefiore Medical Center</organization>
      <phone>718-920-6626</phone>
      <email>befriedm@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

